Drug Type Bispecific antibody |
Synonyms- |
Action antagonists, inhibitors |
Mechanism CD64 antagonists(High affinity immunoglobulin gamma Fc receptor I antagonists), amyloid light chain inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Immunoglobulin Light-Chain Amyloidosis | Preclinical | United States | 05 Dec 2025 |






